SCHEMBL26074118

SCHEMBL26074118

CCNc1ccccc1-c1ccc(-c2cc(C(=O)OC)c3cc(F)ccc3n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 9/20 0.64
▸ DHODH Q02127 7/20 0.54
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ SLC6A4 P31645 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ MAPK1 P28482 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590249 0.91 DHODH (0.66) PLA2G2ADHODHMEN1KMT2AKDM4E
SCHEMBL26074102 0.82 PLA2G2A (0.64) PLA2G2ADHODHMEN1KMT2AKDM4E
SCHEMBL23590116 0.82 DHODH (0.56) PLA2G2ADHODHMEN1KMT2AKDM4E
SCHEMBL26075575 0.82 DHODH (0.44) PLA2G2ADHODHALDH1A1
SCHEMBL23590338 0.82 DHODH (0.58) PLA2G2ADHODHMEN1KMT2AKDM4E
SCHEMBL28475970 0.79 PLA2G2A (0.78) PLA2G2ADHODHKDM4EALDH1A1
SCHEMBL5792945 0.79 PLA2G2A (0.78) PLA2G2ADHODHMEN1KMT2AALDH1A1
SCHEMBL23590232 0.78 DHODH (0.51) DHODHKMT2AKDM4EALDH1A1
SCHEMBL28693800 0.77 KDM4E (0.72) PLA2G2ADHODHMEN1KMT2AKDM4E
SCHEMBL26074099 0.77 PLA2G2A (0.75) PLA2G2ADHODHMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PLA2G2A 1679/4885DHODH 1/4885MEN1 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback